Cancer News and Research

Latest Cancer News and Research

Rexahn announces completion of RX-3117 exploratory Phase I clinical trial in cancer patients

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has completed its exploratory Phase I clinical trial of RX-3117 in cancer patients.

6 Aug 2012

NeoGenomics introduces new molecular assay that detects SF3B1 gene mutations

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced today that it has validated and launched the first molecular assay for clinical use in the United States that detects mutations in the SF3B1 gene (splicing factor 3b, subunit 1).

6 Aug 2012

Nanobiotix, PharmaEngine partner to develop NBTXR3 for cancer

French Nanobiotix S.A. announced today that it entered into a strategic partnership with PharmaEngine, Inc. for the rapid development of NBTXR3, the lead product from the NanoXray pipeline of Nanobiotix.

6 Aug 2012

Nanobiotix, PharmaEngine partner to commercialize NBTXR3 for soft tissue sarcoma

PharmaEngine, Inc. announced today the execution of an exclusive license and collaboration agreement with France-based Nanobiotix S.A. for the development and commercialization of NBTXR3, currently being investigated in a phase I study with soft tissue sarcoma patients.

6 Aug 2012

TWi Pharmaceuticals completes AC-201 phase II study on type II diabetes

TWi Pharmaceuticals, Inc., a specialty pharmaceutical company based in Taiwan, today announced its fully owned subsidiary, TWi Biotechnology, Inc. has completed a multinational phase II dose-ranging study of AC-201, an orally available IL-1 Beta modulator, in 259 patients with type II diabetes uncontrolled on up to three oral medications.

6 Aug 2012

Clovis Oncology, Foundation Medicine enter diagnostic collaboration

Foundation Medicine, Inc. and Clovis Oncology, Inc. announced today that they have entered into a diagnostic collaboration.

6 Aug 2012

Scientists identify key factor that drives resistance to cancer drug

Developing resistance to chemotherapy is a nearly universal, ultimately lethal consequence for cancer patients with solid tumors - such as those of the breast, prostate, lung and colon - that have metastasized, or spread, throughout the body. A team of scientists led by Fred Hutchinson Cancer Research Center has discovered a key factor that drives this drug resistance - information that ultimately may be used to improve the effectiveness of therapy and buy precious time for patients with advanced cancer.

6 Aug 2012

Montefiore launches first fellowship program in Women's Physical Medicine and Rehabilitation

Montefiore Medical Center has launched the nation's first fellowship program in Women's Physical Medicine and Rehabilitation (WPM&R), and established a new clinical program in this specialty.

6 Aug 2012

New sequencing approach can provide more effective method of BRCA1/2 mutational analysis

Individuals with mutations in BRCA1 and BRCA2 genes have a significantly higher risk of developing breast and ovarian cancers. Families at risk have been seeking genetic testing and counseling based on their mutation carrier status, but the standard method of direct sequencing is labor-intensive, costly, and it only targets a part of the BRCA1 and BRCA2 genes.

6 Aug 2012

Neutrophils play an unexpected role in mediating insulin resistance

Researchers at the University of California, San Diego School of Medicine say neutrophils, an abundant type of white blood cell typically tasked with attacking bacteria and other foreign invaders, also plays an unexpected role in mediating insulin resistance - the central characteristic of type 2 diabetes, which afflicts an estimated 26 million Americans.

6 Aug 2012

Novartis, Penn partner to study and commercialize novel cellular immunotherapies for cancer

In an alliance aimed at bringing a new, personalized immunotherapy approach to patients with a wide variety of cancers, the University of Pennsylvania and Novartis announced today an exclusive global research and licensing agreement to further study and commercialize novel cellular immunotherapies using chimeric antigen receptor (CAR) technologies.

6 Aug 2012

Mammalian cells divide when their growth rate hits a specific threshold

It's a longstanding question in biology: How do cells know when to progress through the cell cycle? In simple organisms such as yeast, cells divide once they reach a specific size. However, determining if this holds true for mammalian cells has been difficult, in part because there has been no good way to measure mammalian cell growth over time.

6 Aug 2012

Sanofi-aventis receives FDA approval for Zaltrap to treat colorectal cancer

The U.S. Food and Drug Administration today approved Zaltrap (ziv-aflibercept) for use in combination with a FOLFIRI (folinic acid, fluorouracil and irinotecan) chemotherapy regimen to treat adults with colorectal cancer.

6 Aug 2012

Viewpoints: Romney's 'repeal and replace' pledge; 'Socialized medicine' in the U.S.; Pros and cons of expanding Medicaid

Greg Sargent already took a crack at Mitt Romney's new "Plan for a Stronger Middle Class," but one thing that he didn't get to shouldn't be ignored: Romney is apparently still campaigning on a "repeal and replace" plan on health care reform.

3 Aug 2012

Potential new drug to treat common inherited kidney disease

Scientists at UC Santa Barbara have demonstrated in the laboratory that a new drug is effective in treating a very common kidney disease -- although it will be a few years before it becomes available for clinical testing. The findings resulted from a collaboration between UCSB and a biotech firm based in Indiana. The study is published in this week's Journal of the American Society of Nephrology.

3 Aug 2012

New role for oncogenic signaling pathway in embryonic stem cell self-renewal

Researchers at Mount Sinai School of Medicine, the University of Manchester, and the MD Anderson Cancer Center have found a new role for an oncogenic signaling pathway in embryonic stem cell (ESC) self-renewal and in reprogramming adult cells into an ESC-state, which will aid in the development of future cancer therapies.

3 Aug 2012

Komen ads overstate benefits of mammograms, professors charge

Two Dartmouth health policy experts criticize the national breast cancer charity for using misleading statistics to promote breast cancer screening.

3 Aug 2012

TAT-ARC fusion protein helps treat acute liver failure

Acute liver failure is a life-threatening disease, characterized by a sudden, massive death of liver cells. Unfortunately, few treatment options exist, especially for advanced-stage liver failure. As a last resort a liver transplant may be the only remaining option.

3 Aug 2012

Simpler and more accurate way to test for prostate cancer

An undergraduate student's technique for detecting certain metabolites in urine samples could lead to a simpler and more accurate way to test for prostate cancer.

3 Aug 2012

Allergies may reduce risk of brain cancer

New research adds to the growing body of evidence suggesting that there's a link between allergies and reduced risk of a serious type of cancer that starts in the brain. This study suggests the reduced risk is stronger among women than men, although men with certain allergy profiles also have a lower tumor risk.

3 Aug 2012